Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

Related Articles by Review for PubMed (Select 23436834)

1.

Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA.

AJR Am J Roentgenol. 2013 Mar;200(3):475-83. doi: 10.2214/AJR.12.9049. Review. Erratum in: AJR Am J Roentgenol. 2013 May;200(5):1174.

2.

What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents.

Chikarmane SA, Khurana B, Krajewski KM, Shinagare AB, Howard S, Sodickson A, Jagannathan J, Ramaiya N.

Emerg Radiol. 2012 Dec;19(6):535-46. doi: 10.1007/s10140-012-1052-1. Epub 2012 Jun 7. Review.

PMID:
22673844
3.

Cardiotoxicity of molecularly targeted agents.

Hedhli N, Russell KS.

Curr Cardiol Rev. 2011 Nov;7(4):221-33. Review.

4.

Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.

Mellor JD, Cassumbhoy M, Jefford M.

Asia Pac J Clin Oncol. 2011 Jun;7(2):106-13. doi: 10.1111/j.1743-7563.2011.01394.x. Review.

PMID:
21585689
5.

Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.

Kheir WJ, Sniegowski MC, El-Sawy T, Li A, Esmaeli B.

Surv Ophthalmol. 2014 Sep-Oct;59(5):493-502. doi: 10.1016/j.survophthal.2014.02.004. Epub 2014 Feb 18. Review.

PMID:
25130892
6.

Adverse events of targeted therapies.

Klastersky JA.

Curr Opin Oncol. 2014 Jul;26(4):395-402. doi: 10.1097/CCO.0000000000000096. Review.

PMID:
24825019
7.

Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know?

Rohatgi S, Jagannathan JP, Rosenthal MH, Kim KW, Ramaiya NH, Krajewski KM.

AJR Am J Roentgenol. 2014 Dec;203(6):1353-62. doi: 10.2214/AJR.13.11967. Review.

PMID:
25415715
8.

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.

Zambelli A, Della Porta MG, Eleuteri E, De Giuli L, Catalano O, Tondini C, Riccardi A.

Breast. 2011 Apr;20(2):176-83. doi: 10.1016/j.breast.2010.11.002. Epub 2010 Dec 13. Review.

PMID:
21146409
9.

[Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].

Bartal A, Mátrai Z, Szucs A, Belinszkaja G, Langmár Z, Rosta A.

Orv Hetil. 2012 Jan 15;153(2):66-78. doi: 10.1556/OH.2012.29272. Review. Hungarian.

PMID:
22217686
10.

Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.

Izar B, Rotow J, Gainor J, Clark J, Chabner B.

Pharmacol Rev. 2013 Oct 3;65(4):1351-95. doi: 10.1124/pr.113.007807. Print 2013. Review.

11.

[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].

Sibaud V, Delord JP, Chevreau C, Gangloff D, Garrido-Stowhas I.

Ann Chir Plast Esthet. 2012 Apr;57(2):106-13. doi: 10.1016/j.anplas.2012.02.002. Epub 2012 Mar 15. Review. French.

PMID:
22425393
12.

The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

Ho WL, Wong H, Yau T.

Acta Ophthalmol. 2013 Nov;91(7):604-9. doi: 10.1111/j.1755-3768.2012.02518.x. Epub 2012 Sep 12. Review.

13.

[Radiologic side effects of cancer therapy].

Beule A, Tarkkanen M.

Duodecim. 2015;131(5):448-56. Review. Finnish.

PMID:
26237907
14.

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.

Liu S, Kurzrock R.

Cancer Treat Rev. 2014 Aug;40(7):883-91. doi: 10.1016/j.ctrv.2014.05.003. Epub 2014 May 17. Review.

PMID:
24867380
15.

Advances in the management of cutaneous toxicities of targeted therapies.

Robert C, Sibaud V, Mateus C, Cherpelis BS.

Semin Oncol. 2012 Apr;39(2):227-40. doi: 10.1053/j.seminoncol.2012.01.009. Review.

PMID:
22484194
16.

Ocular toxicity of targeted therapies.

Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL.

J Clin Oncol. 2012 Sep 10;30(26):3277-86. doi: 10.1200/JCO.2011.41.5851. Epub 2012 May 29. Review.

PMID:
22649132
17.

Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.

Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S, Sablin MP, Le Tourneau C.

Eur J Cancer. 2014 Feb;50(3):638-48. doi: 10.1016/j.ejca.2013.10.016. Epub 2013 Nov 17. Review.

PMID:
24256808
18.

Skin toxicity of targeted cancer agents: mechanisms and intervention.

Belum VR, Fontanilla Patel H, Lacouture ME, Rodeck U.

Future Oncol. 2013 Aug;9(8):1161-70. doi: 10.2217/fon.13.62. Review.

PMID:
23902247
19.

Review: side effects of approved molecular targeted therapies in solid cancers.

Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A.

Oncologist. 2007 Dec;12(12):1443-55. doi: 10.1634/theoncologist.12-12-1443. Review.

20.

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Criscitiello C, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ.

Breast Cancer Res. 2012 Jun 19;14(3):209. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk